Search clinical trials for: HDDO-1756

Total 148 results

Hyundai Pharmaceutical Co., LTD.

Completed

HDDO-1756 Bio Equivalence Study

Hyperlipidemias

Korea, Republic of
National Cancer Institute (NCI)

Completed

CDDO to Treat Solid Tumors and Lymphomas

Lymphoma | Solid Tumors

United States
Shire

Completed

Safety and Efficacy of NPS 1776 in the Acute Treatment of Migraine Headaches

Migraine Headache

United States
NeuroBo Pharmaceuticals Inc.

Not yet recruiting

First in Human Study in Subjects With Obesity, But Otherwise Healthy

Obesity

United States
Novo Nordisk A/S

Completed

Research Study of a New Medicine (NNC9204-1706) in People With Overweight or Obesity

Obesity | Metabolism and Nutrition Disorder

United States
Jiangsu HengRui Medicine Co., Ltd.

Completed

A Study to Evaluate the Safety and Efficacy of DDO-3055 in Healthy Volunteers and Patients With Chronic Kidney Disease

Chronic Kidney Disease

China
Jiangsu HengRui Medicine Co., Ltd.

Enrolling by invitation

Multi-dose, Dose Escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of DDO-3055 Tablets in Patients With Anemia of Non-dialysis Chronic Kidney Diseases.

Anemia Associated Chronic Kidney Disease

China
Astex Pharmaceuticals, Inc.

Withdrawn

Study of SGI-1776, a PIM Kinase Inhibitor, in Subjects With Relapsed/Refractory Leukemias

Relapsed/Refractory Leukemias

United States
Jiangsu HengRui Medicine Co., Ltd.

Completed

Food Effect Study of DDO-3055 Tablets in Healthy Subjects

Anemia in Chronic Kidney Disease

China
Glenmark Pharmaceuticals Ltd. India
Glenmark Pharmaceuticals S.A.

Withdrawn

A Clinical Trial to Study the Effects of GRC 17536 in Patients With Painful Diabetic Neuropathy (Painful Extremities Due to Peripheral Nerve Damage in Diabetic Patients)

Painful Diabetic Neuropathy

Germany, United Kingdom
Jiangsu HengRui Medicine Co., Ltd.

Unknown

Multi-dose, Dose Escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of DDO-3055 Tablets in Healthy Subjects.

Renal Anemia
Novo Nordisk A/S

Completed

Investigation of Single Ascending Doses of NNC9204-1706 in Male Subjects Being Overweight or With Obesity

Obesity | Metabolism and Nutrition Disorder

United States
Glenmark Pharmaceuticals Ltd. India
Glenmark Pharmaceuticals S.A.

Completed

A Clinical Trial to Study the Effects GRC 17536 in Patients With Painful Diabetic Peripheral Neuropathy (Painful Extremities Due to Peripheral Nerve Damage in Diabetic Patients).

Painful Diabetic Peripheral Neuropathy

India, Czech Republic, Germany, United Kingdom
BioAge Labs, Inc.

Terminated

Study to Evaluate the Safety, Tolerability, and Efficacy of BGE-175 in Hospitalized Adults With Coronavirus Disease 2019 (COVID-19) That Are Not in Respiratory Failure

Covid19

United States, Brazil, Argentina
AbbVie

Terminated

A Study Evaluating the Safety, Pharmacokinetics and Anti-Tumor Activity of ABBV-176 in Subjects With Advanced Solid Tumors Likely to Express Prolactin Receptor (PRLR)

Advanced Solid Tumors Cancer

United States, Australia, Denmark, Spain
Ikena Oncology
Bristol-Myers Squibb

Completed

A Phase 1a/b Study of IK-175 as a Single Agent and in Combination With Nivolumab in Patients With Locally Advanced or Metastatic Solid Tumors and Urothelial Carcinoma

Neoplasms | Neoplasm Metastasis | Solid Tumor | Metastatic Cancer | Bladder Cancer | Advanced Solid Tumor | Advanced Cancer | Urothelial Carcinoma Bladder | Urothelial Carcinoma | Metastatic Urothelial Carcinoma | Solid Tumor, Adult | Bladder Disease | Solid Carcinoma | Neoplasm Malignant | Neoplasm, Bladder | Locally Advanced... and other conditions

United States
National Institute of Mental Health (NIMH)

Completed

Assessment of [11C]ER176 to Image Translocator Protein in Brain and Whole Body of Healthy People

Pharmacokinetics | Adult

United States
Avid Radiopharmaceuticals

Completed

18F-LY3950321-01 Biodistribution and Safety Study

Radiation Exposure | Diagnostic Agent Adverse Reaction

United States
Arch Oncology

Completed

Study of AO-176 as Monotherapy and in Combination With Bortezomib/Dexamethasone in Relapsed/Refractory Multiple Myeloma

Multiple Myeloma

United States
Astex Pharmaceuticals, Inc.

Terminated

Safety of SGI-1776, A PIM Kinase Inhibitor in Refractory Prostate Cancer and Relapsed/Refractory Non Hodgkin's Lymphoma

Prostate Cancer | Non-Hodgkins Lymphoma

United Kingdom, United States
Boehringer Ingelheim

Completed

Relative Bioavailability of 1 mg and 10 mg BI 1356 BS as Powder in the Bottle (PIB) to 1 mg and 10 mg BI 1356 BS as Tablets as Single Oral Administration in Healthy Male Volunteers Including the Influence of Food on the Bioavailability of 10 mg BI 1356 BS

Healthy
University of Aarhus
Aarhus University Hospital; Aalborg University

Completed

TETRA (Terrestrial Trunked Radio)

Cognitive Performance | Well-Being

Denmark
HiDO Technologies

Completed

Automated Medication Platform With Video Observation and Facial Recognition to Improve Adherence to Antiretroviral Therapy in Patients With HIV/AIDS

HIV Infections

United States
SAb Biotherapeutics, Inc.
Hvivo

Active, not recruiting

Study of SAB-176 in Healthy Adult Participants

Influenza A H1N1

United Kingdom
Arch Oncology
Merck Sharp & Dohme LLC

Completed

AO-176 in Multiple Solid Tumor Malignancies

Solid Tumor

United States
Hasselt University

Recruiting

Indoor Air Quality Monitoring and Impact on Children's Health (LEARN)

Cognition

Belgium
Boehringer Ingelheim

Completed

Efficacy and Safety of 3 Doses of BI1356 (Linagliptin) in Type 2 Diabetes Patients

Diabetes Mellitus, Type 2

United States, Australia, Canada, Czech Republic, Russian Federation, Ukraine
Boehringer Ingelheim

Completed

Safety and Efficacy of Linagliptin (BI 1356) Plus Metformin in Type 2 Diabetes, Factorial Design

Diabetes Mellitus, Type 2

Canada, Croatia, Estonia, France, Germany, India, Lithuania, Mexico, Netherlands, Romania, Russian Federation, Sweden, Tunisia, Ukraine
Boehringer Ingelheim

Completed

Bioavailability of BI 1356 After Single Oral Administration Given as Different Tablet Formulation in Healthy Male Volunteers

Healthy
Bridge Biotherapeutics, Inc.

Terminated

Phase 1/2 Study of BBT-176 in Advanced NSCLC With Progression After EGFR TKI Treatment

NSCLC

Korea, Republic of
SAb Biotherapeutics, Inc.

Active, not recruiting

Safety, Tolerability, and Pharmacokinetics of SAB-176 in Healthy Participants

Influenza | Influenza Type B | Influenza Type A

United States
Argorna Pharmaceuticals Co., LTD

Completed

A Phase I/II Study to Evaluate a SARS-CoV-2 mRNA Vaccine in Healthy Adults

SARS-CoV-2

China
Boehringer Ingelheim

Completed

Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of BI 1356 BS as Tablet in Patients With Type 2 Diabetes

Diabetes Mellitus, Type 2
European Organisation for Research and Treatment...

Recruiting

SPECTA: Screening Cancer Patients for Efficient Clinical Trial Access (SPECTA)

All Tumor Types

Spain, United Kingdom, Croatia, Belgium, France, Netherlands, Italy, Germany, Portugal, Austria, Cyprus, Czechia, Estonia, Greece, Lithuania, Poland, Romania, Slovenia, Switzerland, Serbia
University of Pennsylvania
Takeda; Corporal Michael J. Crescenz VA Medical Center

Withdrawn

An Open Label Single-arm Phase 4 Study of Vedolizumab in Subjects With Newly Diagnosed Active Ulcerative Colitis

Ulcerative Colitis

United States
Boehringer Ingelheim

Completed

BI 1356 BS in Japanese Patients With Type 2 Diabetes Mellitus

Diabetes Mellitus, Type 2
Val Lowe

Enrolling by invitation

Targeting Neuroinflammation as a Contributing Pathology in Alzheimer's Disease Dementia

Alzheimer Disease

United States
Penn State University

Terminated

The Role of Satiety in the Effect of Portion Size on Intake

Feeding Behavior

United States
Laboratorios Sophia S.A de C.V.

Completed

Clinical Trial to Compare the Safety and Efficacy of Nanodrop® (PRO-176/I)

Dry Eye

Mexico
National Institute of Allergy and Infectious Diseases...

Completed

EBA-175 RII-NG Malaria Vaccine Administered Intramuscularly in Semi-immune Adults

Plasmodium Falciparum Malaria

Ghana
Boston University
Innovations for Poverty Action

Completed

Evaluation of Novartis Access; a Non-communicable Disease (NCD) Access Initiative

Cardiovascular Disease | Breast Cancer | Asthma | Diabetes Type II
Boehringer Ingelheim

Completed

Pharmacokinetics and Pharmacodynamics of Multiple 5 mg Doses of BI 1356 p.o. Given Once Daily Compared to Multiple 2.5 mg Doses Given Twice Daily in Healthy Male and Female Volunteers

Healthy
Hyundai Pharmaceutical Co., LTD.

Completed

HDDO-1614 Bio Equivalence Study

Osteoporosis

Korea, Republic of
Boehringer Ingelheim

Completed

Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single Rising Doses of BI 1356 BS in Healthy Male Volunteers

Healthy
Milton S. Hershey Medical Center

Recruiting

AGN-CognI.Q Acute Dose Safety and Pharmacokinetics Dose-Response in Prostate Cancer Patients

Prostate Cancer

United States
Penn State University
Jenny Craig, Inc.

Completed

The Influence of Satiation Measures on the Portion Size Effect

Feeding Behavior

United States
Boehringer Ingelheim

Completed

Bioavailability of Combination Tablet BI 1356/Metformin Compared With Single BI 1356 and Metformin Administered Together to Healthy Male and Female Subjects

Healthy
Boehringer Ingelheim

Completed

Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single Rising Oral Doses and Multiple Rising Oral Doses of BI 1356 BS in Healthy Male Volunteers

Healthy
Click Therapeutics, Inc.
Boehringer Ingelheim

Completed

A Study to Evaluate the Overall Effects of Treatment With Abbreviated CT-156 in People With Schizophrenia

Schizophrenia

United States
AbbVie
Genentech, Inc.; Amgen

Terminated

A Study of Venetoclax and AMG 176 in Patients With Relapsed/Refractory Hematologic Malignancies

Acute Myeloid Leukemia | Non-Hodgkin's Lymphoma | Diffuse Large B-cell Lymphoma

United States, Australia, Germany

3

Subscribe